Faculty, Staff and Student Publications

Language

English

Publication Date

1-1-2023

Journal

Antibody Therapeutics

DOI

10.1093/abt/tbac027

PMID

36683763

PMCID

PMC9847341

PubMedCentral® Posted Date

November 2022

PubMedCentral® Full Text Version

Post-print

Abstract

Acetaminophen (APAP) overdose is a leading cause of acute liver injury in the USA. The chitinase 3-like-1 (Chi3l1) protein contributes to APAP-induced liver injury (AILI) by promoting hepatic platelet recruitment. Here, we report the development of a Chi3l1-targeting antibody as a potential therapy for AILI. By immunizing a rabbit successively with the human and mouse Chi3l1 proteins, we isolated cross-reactive monoclonal antibodies (mAbs) from single memory B cells. One of the human and mouse Chi3l1 cross-reactive mAbs was humanized and characterized in both

Keywords

Chi3l1, acetaminophen, liver injury, antibody therapy, rabbit antibody, humanized antibody

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.